Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of DTP-HB-Hib (New Hep B Bulk) in Infants
NCT05482282Phase 3Withdrawn
- Sponsor
- Bio Farma
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatitis B (HBV), diphtheria, Tetanus and 2 more (2 arms), sponsored by Bio Farma. Primary endpoint: Protectivity of DTP-HB-Hib Vaccine at 28 days. Planned start Dec 2025; status: withdrawn.
02
Conditions
hepatitis B (HBV)diphtheriaTetanuspertussisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT05482282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05482282.